Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma

Gynecologic Oncology

Volumn 83, Issue 2, 2001, Pages 198-204

  Tournigand, Christophe ^a   Louvet, Christophe ^a   Molitor, Jean Luc ^a   Dehni, Nidal ^a   Lejeune, Véronique ^a   Sezeur, Alain ^b   Pigne, Alain ^c   Marpeau, Loïc ^d   Cady, Jean ^e   De Gramont, Aimery ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b Hopital des Diaconesses   (France)

^c HÔPITAL ROTHSCHILD   (France)

^d HÔPITAL CHARLES NICOLLE   (France)

^e Clinique Geoffroy Saint Hilaire   (France)

Author keywords

Cisplatin; Early debulking surgery; Epirubicin; Intraperitoneal chemotherapy; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; MITOXANTRONE;

ADULT; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DRUG RESPONSE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NEUROPATHY; OVARY CARCINOMA; PAIN; PRIORITY JOURNAL; SECOND LOOK SURGERY; TREATMENT OUTCOME;

EID: 0034762123     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6363     Document Type: Article

References (23)

1. Epithelial ovarian cancer
2. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer
3. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study
4. A meta-anlysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives
5. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: Impact on survival
6. Does debulking surgery improve survival in biologically agressive ovarian carcinoma?
7. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer
8. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer
9. Updated analysis shows a highly significant improved overall survival for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: Mature results of the EORTCGCCG, NOCOVA
10. Impact of doxorubicin on survival in advanced ovarian cancer
11. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis
12. Meta-analysis of cisplatin, doxorubicin and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma
13. Meta-analyses of chemotherapy regimens for ovarian carcinoma: A reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide
14. Sequential cisplatin-doxorubicin, early debulking surgery and intraperitoneal chemotherapy in advanced ovarian cancer
15. Bi-weekly schedule of high-dose folinic acid, 5-fluorouracil bolus and infusion in pretreated advanced epithelial ovarian cancer: A phase II study
16. Intraperitoneal chemotherapy in the treatment of ovarian cancer
17. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
18. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer
19. Non parametric estimation from incomplete observations
20. Cisplatin/paclitaxel vs carboplatin/paclitaxel as first line treatment in ovarian cancer
21. Randomized phase III study if intravenous cisplatin/paclitaxel versus moderately high dose IV carboplatin followed by IV paclitaxel and intraperitoneal cisplatin in optimal residual ovarian cancer: An intergroup trial (GOG, SWOG, ECOG)
22. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: Evolution of a regimen
23. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment